mediated angioedema is of critical importance to prevent morbidity and mortality. 2 The ability to diagnose bradykinin-mediated angioedema with normal C1 inhibitor (C1INH), however, has been severely limited by the lack of any available diagnostic tests.
Hereditary angioedema (HAE) due to C1INH deficiency (HAE-C1INH) and acquired C1INH deficiency are the best characterized forms of bradykinin-mediated angioedema. [3] [4] [5] [6] A novel form of HAE with normal C1INH (HAE-nl-C1INH) was initially described in 2000. 7, 8 Subsequently, a minority of HAE-nl-C1INH patients were found to have mutations in F12 (the gene encoding FXII; HAE-FXII) that segregated with disease activity. [9] [10] [11] [12] HAE-FXII is autosomal dominant with low penetrance. 13 Most recently, mutations in angiopoietin-1 and plasminogen have also been linked to HAE-nl-C1INH. 14, 15 Most HAE-nl-C1INH patients, however, do not have a known mutation and are called HAE-unknown (HAE-U). Distinguishing HAE-U from idiopathic histaminergic angioedema (IHA) is very challenging due to the lack of any definitive biomarker for either condition. Currently, the diagnosis of HAE-U is based on consensus clinical criteria, although the sensitivity and specificity of this approach are unknown. 16 Another group of angioedema patients is clinically similar to HAE-U but lack a compelling family history of angioedema. This group has been classified as idiopathic non-histaminergic angioedema (INHA) and also lacks any biomarker to establish the diagnosis. 17 Recent evidence strongly supports the hypothesis that HAE-FXII is mediated by bradykinin. 18, 19 Circumstantial evidence suggests that HAE-U and INHA are also bradykinin-mediated 20, 21 and may respond to bradykinin-targeted medications. 13, [22] [23] [24] The lack of a validated clinical biomarker to differentiate bradykinin-mediated angioedema from histaminemediated angioedema has caused considerable difficulty for patients and physicians. Many patients are denied access to medicines that appear to be helpful because of the lack of a clear-cut diagnosis. Alternatively, some patients are labelled as having HAE-nl-C1INH and prescribed bradykinintargeted medications despite very weak evidence that their angioedema is bradykinin-mediated. Development of a robust clinical assay to help identify patients with bradykinin-mediated angioedema is an urgent unmet need with major clinical and economic implications.
In this study, we describe a simple assay that discriminates histamine-from bradykinin-mediated angioedema. This assay is based on activation of plasma kallikrein following ex vivo stimulation of the contact system in plasma. Utilizing a threshold dose of the stimulator, we could differentiate subjects with bradykinin-mediated from IHA without urticaria. We propose that this assay can help identify patients with possible HAE-U or INHA who could benefit from a trial of a bradykinin-targeted medication. By segregating these patients from IHA, this assay may also facilitate efforts to identify the underlying mechanisms of bradykinin-mediated angioedema with normal C1INH. were further classified based on probability using two pre-defined criteria not in the consensus guidelines: (a) history of rapid and durable responses to a bradykinin-targeted medication; and (b) either predominantly documented visible angioedema; or in patients with predominant abdominal symptoms, evidence of bowel wall edema documented by CT or MRI. To be classified as high probability, subjects needed to meet both additional criteria. A negative response to either of these reduced the probability to moderate, and negative responses to both reduced the probability to low. 
| ME TH ODS

| Human subjects
| Blood drawing and processing
| Reagents and chemicals
The following reagents and chemicals were purchased: dextran sul- Ten minutes prior to the assay, the stock Z-Phe-Arg-AMC-HCl was diluted to the final concentration with filtered deionized H 2 0 and then kept at room temperature in the dark until used.
| Plasma kallikrein fluorometric activity assay
Plasma aliquots were thawed in a 37°C water bath for 4 minutes immediately prior to performing the assay. The assay was performed 
| Plasma high molecular weight kininogen (HMWK) immunoblotting
Citrated plasma samples (10 μL) were incubated with varying concentrations of DXS (10 μL) for 30 minutes at 37°C, and the stimulation stopped by dilution with an equal volume of 2X Laemmli loading buffer. Immunoblotting for HMWK was performed under both reducing and non-reducing conditions as previously described. 
| Data and statistical analysis
GraphPad PRISM 7.0a software for MAC was used to perform linear regression analysis and slope calculations (La Jolla, CA, USA). JMP Statistical Analysis Software (SAS) was used for data analysis (Cary, NC, USA). Group comparisons used the Wilcoxon signed-rank test.
Differences with a P value <0.05 were considered significant. Receiver operator curve (ROC) analysis was performed using a web-based calculator.
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3 | RESULTS
| Subject demographics and phenotyping
A total of 154 unrelated research subjects were enrolled. The final clinical phenotype for each subject reflected the initial consultative evaluation as well as information collected on clinical follow-up.
Every subject was independently phenotyped by at least two expert angioedema clinicians who were blinded to the experimental results.
In the few cases where there was a difference in initial phenotype decision, subjects' clinical data were reviewed by all 3 experts until a unanimous consensus was reached. Random codes were broken, and experimental assay results linked to the subjects only after all the clinical phenotyping was finalized.
Of 154 subjects, 37 were excluded because they were found to have concomitant urticaria. Subjects considered to have low probability of HAE-nl-C1INH or INHA (n = 7) were also excluded. Eight subjects were felt to have features of both bradykinin-mediated and histamine-mediated angioedema. These subjects were classified in a separate group, identified as intermediate and excluded from the analysis. Additional excluded subjects were as follows: 3 subjects diagnosed with ACE inhibitor associated angioedema; 2 subjects with complex seizure disorders requiring use of multiple drugs; 2 subjects whose plasma was not processed in a timely fashion; and 5 subjects adjudicated not to have angioedema. This left 90 subjects in the analysed cohort. Subject demographics of the analysed cohort are shown in Table 1 . One of the 20 subjects identified as HAE-nl-C1INH was found to have HAE-XII (T309K).
| Spontaneous kallikrein activity does not distinguish HAE-nl-C1INH or INHA from IHA
Spontaneous plasma kallikrein amidolytic activity has been reported to identify patients with HAE-nl-C1INH. 21 As shown in Table 1 , we observed a modest increase in spontaneous kallikrein activity only in the C1INH-deficient subjects. We also failed to detect any increase in spontaneous kallikrein activity in HAE-nl-C1INH or INHA subjects who were actively swelling or had experienced an angioedema attack within 1 day of the blood draw (data not shown).
| Key features of the threshold-stimulated kallikrein assay
We investigated whether plasma kallikrein activity stimulated by a minimal threshold dose of DXS could identify bradykinin-mediated angioedema subjects. Ten μg/mL DXS stimulated maximal kallikrein activity in all subjects and failed to discriminate between the groups LARA-MARQUEZ ET AL. Five μg/mL DXS gave a near maximal response but failed to clearly discriminate between the subjects. After 2.5 μg/mL DXS, kallikrein activity was clearly increased in the HAE-C1INH, INHA and HAE-nl-C1INH subjects compared to the IHA and NSC subjects. At 1.25 μg/mL DXS and below, only the HAE-C1INH subject showed significant kallikrein activity.
We investigated the specificity and reproducibility of the kallikrein assay. Because the fluorometric substrate used in our assay could potentially be cleaved by other proteases, we assessed the dependence of the cleavage on activation of the plasma contact system. DXS stimulated cleavage of the substrate was completely abrogated in normal plasma by pre-incubation with corn trypsin inhibitor, Includes the HAE-FXII subject. *P < 0.05 compared to histaminergic AE. **P < 0.01 compared to histaminergic AE.
F I G U R E 1 Dextran sulfate stimulates kallikrein activity in a dose-dependent manner. Plasma was stimulated ex vivo with various doses of dextran sulfate (DXS) as indicated, and plasma kallikrein activity measured as relative fluorescence units (RFU) over 30 min. BG refers to background or spontaneous kallikrein activity. Panels are as follows: A, non-swelling control; B, histaminergic angioedema; C, HAE-C1INH; D, HAE-FXII; E, HAE-U; and F, INHA a potent and highly specific FXII inhibitor (Figure 2A) . Similarly, we observed no RFU over the 30-minute assay when prekallikrein deficient plasma was stimulated with 5 ug/ml DXS ( Figure 2B ). These results confirm that the DXS-stimulated activity measured in our assay was FXII-and plasma kallikrein-dependent.
We assessed the reproducibility of the assay both in multiple replicates performed in a single assay as well as in multiple aliquots from the same subject analysed on different days. The average variance of multiple replicates of the same sample run on the same day averaged 7.0%. Variance of the plasma sample from seven different subjects run on separate days was 14.5%.
| The threshold-stimulated kallikrein assay distinguishes subjects with HAE-nl-C1INH or INHA from IHA
We analysed kallikrein activity in the entire cohort of subjects using plasma samples that were stimulated with DXS at 0, 1.25, 2.5 and 5.0 μg/mL. Table 1 shows that 2.5 and 5.0 μg/mL DXS provided significant separation in kallikrein activity between the presumed bradykinin-mediated angioedema subjects (HAE-C1INH, acquired C1INH deficiency, HAE-nl-C1INH and INHA) and non-bradykinin-mediated angioedema subjects (IHA and NSC).
Sensitivity and specificity of the stimulated kallikrein activity using 2.5 or 5.0 μg/mL DXS for the diagnosis of HAE-nl-C1INH or INHA were assessed based on our clinical phenotyping utilizing the kallikrein activity measured in the NSC group (mean -170.8; SD -
171.4).
We performed a sensitivity analysis, using the mean NSC kallikrein activity plus either 1, 2 or 3 standard deviations (75-99.75
confidence interval) as the upper limit for kallikrein activity. The sensitivity analysis was performed using four subject populations: (a) entire cohort; (b) entire cohort minus HAE-U or INHA subjects who had received a bradykinin-targeted medication anytime from just before to 6 days prior to the blood draw; (c) all subjects minus the C1INH deficient subjects; and (d) all subjects minus the C1INH deficient subjects as well as subjects who had received a bradykinin-targeted medication within the prior 6 days. Table 2 shows the predictive value for the kallikrein assay (Table 2a after stimulating with 2.5 μg/mL and Table 2b after stimulating with 5.0 μg/mL DXS). The positive predictive value (PPV), negative predictive value (NPV) and odds ratio (OR) are all considerably higher after stimulation with 2.5 μg/mL DXS compared to 5.0 μg/mL DXS. Therefore, we concentrated on the 2.5 μg/mL DXS results. As expected, the sensitivity decreases and the specificity increases as the stringency of the upper limit of normal is increased.
The PPV ranged from (80%-100%) while the NPV was more variable (63.33%-89.47%). Excluding subjects who had recently received a bradykinin-targeted medication improved the NPV (85.71%-89.47%),
suggesting that the medication may have interfered with the assay.
Individual 2.5 μg/mL DXS-stimulated kallikrein activity is shown in Figure 3A while Figure 3B shows the activity in subjects who had not recently received a bradykinin-targeted medication. In every case, HAE-C1INH, HAE-nl-CINH and INHA groups had significantly elevated kallikrein activity compared to IHA and NSC groups. No significant differences were seen between the HAE-U-, INHA-and C1INH-deficient groups. As our HAE-nl-C1INH and INHA groups are predominantly female, we asked whether there was a gender difference in the assay. We found no difference in the 2.5 μg/mL DXS-stimulated kallikrein activity between females vs males in our IHA and NSC groups (data not shown).
Receiver operator curve (ROC) analysis is a standard method to evaluate the value of a diagnostic test. We evaluated the thresholdstimulated kallikrein assay for the diagnosis of recurrent angioedema without urticaria in subjects who had not recently received bradykinin-targeted treatment as this represents the clinical scenario for which the test would be most useful. As shown in Figure 4 , the kallikrein assay showed excellent characteristics as a diagnostic test based on area-under-the curve >0.91 in the ROC analysis.
| DXS-stimulated kallikrein activity can be modelled using rKLKB1
We constructed standard curves of kallikrein activity using rKLKB1, performed in an identical manner to the threshold-stimulated kallikrein assay except that varying amounts of rKLKB1 were added in place of plasma. Figure 5 shows the linear characteristics of the rKLKB1 activity in this assay. By interpolating the mean kallikrein activity, we could estimate that the mean amount of kallikrein 
| Increased threshold-stimulated kallikrein activity correlates with increased susceptibility to ex vivo HMWK cleavage
In a limited number of subjects, we assessed whether threshold DXS-stimulated kallikrein activity also tracked with enhanced susceptibility to DXS-induced HMWK cleavage. In this report, we describe a threshold-stimulated kallikrein assay that provides a new tool to positively identify patients with HAE-U and INHA.
Clinical phenotyping was critical to the analysis and utilized stringent criteria. First, we utilized current consensus guidelines. Second, phenotype was determined by comprehensive clinical evaluation and P < 0.001 P < 0.01 P < 0.01 P < 0.001 P < 0.001 P < 0.001 P < 0.005 P < 0.005 P < 0.001 P < 0.001 P < 0.005
F I G U R E 3 Kallikrein activity is increased in subjects in the HAE-nl-C1INH, INHA and C1INH deficiency groups. Individual results of plasma kallikrein activity after ex vivo stimulation with dextran sulfate (DXS) 2.5 μg/mL are shown. Mean kallikrein activity is represented by the horizontal line for each group. Differences that were statistically significant by Wilcoxon test are shown. Panel A: all subjects. Panel B: subjects receiving a bradykinin-targeted medication within 6 d of the sample collection were excluded F I G U R E 4 Receiver operating curve for the stimulated plasma kallikrein activity assay. The receiver operator curve (ROC) was generated using all subjects with recurrent angioedema without urticaria who had not received a bradykinin-targeted medication within 6 d of the sample collection. The line of no-discrimination is shown as a dashed line F I G U R E 5 Recombinant human plasma kallikrein yields a linear curve that can be used to standardize the assay. Various doses of rKLKB1 were added in place of subject plasma and the activity measured as described chart review by at least two physicians with expertise in angioedema. Third, subjects were subdivided into high, moderate or low probability categories based on additional strict criteria. Fourth, in the rare cases of disagreement about diagnosis or probability, all three expert clinicians reviewed the data together until a consensus was reached. Clinicians were blinded to the assay results until phenotyping was completed.
Two groups were excluded from further analysis. The first consisted of seven subjects classified as HAE-U low probability. These subjects reported predominantly episodic abdominal pain without documented imaging showing bowel wall edema and did not report clear benefit from treatment with a bradykinin pathway acting drug.
While these subjects appeared to meet the consensus criteria for HAE-U, our clinical impression was that they did not have true bradykinin-mediated angioedema and likely did not have angioedema.
When the kallikrein data were unblinded, we found that each of these subjects had normal kallikrein activity-corroborating the clinical impression. The second group consisted of eight subjects who could not be unequivocally phenotyped by our clinical criteria. These subjects reported a partial response to treatment with high-dose antihistamines but also described significant improvement when treated with a bradykinin-targeted medication. Interestingly, kallikrein activity in this group was elevated in five of the eight subjects, suggesting a possible mixed pathophysiology in at least some of these individuals.
Increased threshold-stimulated kallikrein activity was highly correlated with clinical phenotype. Most new patients with recurrent angioedema without urticaria will not have been exposed to a bradykinin pathway acting drug. In these patients, we found a PPV ranging from 85.71% to 89.47% and a NPV ranging from 85.71% to 89.47% The threshold-stimulated kallikrein assay should be adaptable to clinical practice. Samples can be stored at −80°C for at least a month prior to assay, the assay itself is relatively simple, fast, and rKLKB1 can be used to standardize the assay allowing comparisons between results obtained at different times or locations. The assay is entirely dependent on activation of the plasma contact system and is highly reproducible. The receiver operating characteristic curve of the assay appears excellent, supporting the potential clinical utility of the assay. Limitations of the assay include the need to collect the blood sample using good technique with rapid processing of the sample. It is important to note that recently administered bradykinintargeted medications may interfere with the assay, although this has not been specifically tested.
Several other assays have been reported to provide useful information in diagnosing HAE-U or INHA. Spontaneous kallikrein chromogenic activity was reported to identify HAE-nl-C1INH patients. 21 We failed to confirm any increase in spontaneous kallikrein activity in our HAE-nl-C1INH subjects. Decreased levels of PAI-2 in patients with HAE-XII and HAE-U were reported 28 ; however, subsequent reports failed to confirm the initial observation.
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F I G U R E 6 Subjects with bradykinin-mediated angioedema show cleavage of high molecular weight kininogen at a lower dose of dextran sulfate (DXS) than histaminergic angioedema or non-swelling control subjects. Plasma was incubated with various doses of DXS then immunoblotted for high molecular weight kininogen under reducing conditions. The intact one-chain kininogen migrates at an apparent molecular weight of 110 kD while the cleaved light chain appears as 62 and 50 kD bands. The relative fluorescence units (RFU) values from the same plasma samples stimulated with DXS 2.5 μg/mL are shown. The panels are as follows: A, non-swelling control; B, histaminergic angioedema; C, HAE-C1INH; D, HAE-FXII; E, HAE-U; and F, INHA
In conclusion, we report a novel biomarker for the diagnosis of HAE-U and INHA. The threshold-stimulated kallikrein assay shows high specificity and positive likelihood ratio for presumed bradykinin-mediated angioedema. The lack of an existing diagnostic test or biomarker for HAE-U or INHA has caused substantial difficulties for patients and physicians resulting in both the failure to treat patients with severe life-threatening angioedema with appropriate medications as well as inappropriate use of costly medications. The inability to establish an accurate diagnosis also severely hampers the ability to conduct genetic studies or therapeutic trials due to the non-homogeneity of the population. We propose that the threshold-stimulated kallikrein assay can be adapted for clinical use and may improve patient care while aiding future studies aimed at identifying specific causes of bradykinin-mediated angioedema.
